Dallas, TX – August 17, 2026 – Alpha Cognition Inc. (NASDAQ: ACOG) reported strong second-quarter results for its Alzheimer's treatment ZUNVEYL, with net product revenue jumping 71% sequentially to $6.0 million, according to an update from Stonegate Capital Partners. The growth was driven by a 37% increase in bottles dispensed, reaching 8,294, and June recorded the strongest demand month since launch at 2,997 bottles.
The results come amid a backdrop of slower payer implementation, with downstream pharmacy benefit manager (PBM) coverage still at approximately 16%. However, Stonegate notes that the quarter's quality was better than the access environment suggests, as prescriptions, repeat use, and facility adoption advanced without broader formulary activation. There was no material stocking benefit, indicating that the revenue growth was fueled by genuine underlying demand and improved commercial execution.
Key metrics show broadening adoption and deepening utilization. The company saw 1,347 quarterly prescribers, 1,024 repeat prescribers, and 1,908 cumulative writers, with 1,095 long-term care (LTC) facilities generating prescriptions during the quarter. This expansion in both breadth and depth positions the company well for future growth, especially as payer access remains an incremental opportunity.
“The core setup is increasingly breadth + depth + payer upside: white space remains across homes and physicians, utilization is deepening, and broader PBM implementation remains incremental to growth,” the Stonegate update stated.
Alpha Cognition also continues to balance commercial investment with a growing evidence base. The company lowered its FY26 R&D and SG&A guidance to $50 million to $54 million while maintaining its 2027 operating profitability target. Several potential milestones are on the horizon, including CONVERGE data expected in 3Q26, the ongoing RESOLVE trial, and the sublingual program, which is gated by comparative PK results.
The announcement from Stonegate Capital Partners provides updated coverage on Alpha Cognition, highlighting the company's progress in the competitive Alzheimer's market. With a significant unmet need for new treatments, ZUNVEYL's performance could signal a shift in the landscape, offering hope to patients and healthcare providers.
For more details, the full announcement is available at Stonegate Capital Partners.
